All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine significantly decreases the risk of infection and COVID-19 clinical events in the general population. However, there is ambiguity surrounding the risk-benefit balance of SARS-CoV-2 mRNA vaccines in patients with SLE.
Kikuchi et al.1 recently published an article in Immunological Medicine, assessing the effects of SARS-CoV-2 mRNA vaccination, including disease flare rates, neutralizing antibody titers, adverse reactions, and associated factors, in patients with SLE. Here, we summarize their findings.
Figure 1. Comparison in A flares, B disease activity, and C–E serological parameters between the vaccine-administered patients with SLE and the unvaccinated controls*
dsDNA, double-stranded deoxyribonucleic acid; SLEDAI, SLE Disease Activity Index.
*Data from Kikuchi, et al.1
†Error bars represent the interquartile range; change (∆) was calculated by subtracting the baseline visit from the subsequent visit.
Statistical significance was set at p < 0.05.
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox